STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMA
  4. [Form 4] ImageneBio, Inc. Insider Trading Activity

ImageneBio (IMA) director granted 15,600 options at $5.45 strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ImageneBio, Inc. director Jonathan Jian Wang received a grant of stock options covering 15,600 shares of common stock. The options have an exercise price of $5.45 per share and expire on June 16, 2036.

The options vest in full on the earlier of the first anniversary of the grant date, the company’s next annual meeting, or a change of control under the 2025 Equity Incentive Plan.

Positive

  • None.

Negative

  • None.
Insider Wang Jonathan Jian
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 15,600 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 15,600 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 15,600 options Stock Option (right to buy) granted to director on June 16, 2026
Exercise price $5.45 per share Strike price for the 15,600 stock options
Expiration date June 16, 2036 Option expiration under the grant
Underlying shares 15,600 shares Common stock underlying the granted options
Post-grant derivative holdings 15,600 options Total stock options held following the reported transaction
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price: "5.4500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
2025 Equity Incentive Plan financial
"as defined in the Issuer's 2025 Equity Incentive Plan."
change of control financial
"the date of the Issuer's next annual meeting or a change of control"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.
vest in full financial
"The shares vest in full upon the earlier to occur of the first anniversary"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wang Jonathan Jian
(Last)(First)(Middle)
C/O IMAGENEBIO, INC.
12526 HIGH BLUFF DRIVE
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ImageneBio, Inc. [ IMA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$5.4506/16/2026A15,600 (1)06/16/2036Common Stock15,600$015,600D
Explanation of Responses:
1. The shares vest in full upon the earlier to occur of the first anniversary of the date of grant, the date of the Issuer's next annual meeting or a change of control as defined in the Issuer's 2025 Equity Incentive Plan.
/s/ Kristin Yarema, Attorney-in-Fact06/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ImageneBio (IMA) report for Jonathan Jian Wang?

ImageneBio reported that director Jonathan Jian Wang received a grant of 15,600 stock options. These options give him the right to buy ImageneBio common shares at a fixed exercise price, subject to vesting conditions tied to time and corporate events.

How many ImageneBio (IMA) stock options were granted and at what price?

Jonathan Jian Wang was granted 15,600 stock options for ImageneBio common stock at an exercise price of $5.45 per share. This means he can purchase up to 15,600 shares at $5.45 once the options vest, before they expire.

When do Jonathan Jian Wang’s ImageneBio (IMA) stock options vest?

The options vest in full upon the earliest of three events: the first anniversary of the grant date, the date of ImageneBio’s next annual meeting, or a qualifying change of control as defined in the company’s 2025 Equity Incentive Plan.

When do the granted ImageneBio (IMA) stock options expire?

The 15,600 stock options granted to Jonathan Jian Wang expire on June 16, 2036. He must exercise any vested options before this expiration date; after that, unexercised options will no longer be valid or exercisable.

Is Jonathan Jian Wang’s ImageneBio (IMA) option grant an open-market purchase?

No. The filing classifies this as a grant or award acquisition of derivative securities, not an open-market purchase. The options were awarded at no upfront cost, with a fixed $5.45 exercise price payable only if and when they are exercised.